MedTrace Logo

Ticagrelor CytoSorb Hemoadsorption

NCT04131959 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-03-09

Study results available
· View outcomes & findings →

Summary

TISORB is a study to show that the CytoSorb device removes ticagrelor from blood during surgery in patients who need emergency surgery on their heart. The hypothesis of TISORB is that removal of ticagrelor by the CytoSorb device during surgery will decrease the risk for surgical bleeding from ticagrelor.

Conditions

  • Emergent Cardiothoracic Surgery
  • Bleeding
  • Drug Removal

Interventions

DEVICE

CytoSorb 300 mL device

Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass

Sponsors & Collaborators

  • CytoSorbents, Inc

    lead INDUSTRY

Principal Investigators

  • Tom Clutton-Brock, MB, ChB · NIHR Trauma Management, MedTech Cooperative

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-29
Primary Completion
2021-05-04
Completion
2021-05-04
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04131959 on ClinicalTrials.gov